Long, Georgina V
Atkinson, Victoria
Cebon, Jonathan S
Jameson, Michael B
Fitzharris, Bernie M
McNeil, Catriona M
Hill, Andrew G
Ribas, Antoni
Atkins, Michael B
Thompson, John A
Hwu, Wen-Jen
Hodi, F Stephen
Menzies, Alexander M
Guminski, Alexander D
Kefford, Richard
Kong, Benjamin Y
Tamjid, Babak
Srivastava, Archana
Lomax, Anna J
Islam, Mohammed
Shu, Xinxin
Ebbinghaus, Scot
Ibrahim, Nageatte
Carlino, Matteo S
This article is maintained by: Elsevier
Article Title: Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
Journal Title: The Lancet Oncology
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S1470-2045(17)30428-X
CrossRef DOI link to the associated document: https://doi.org/10.1016/S1470-2045(17)30518-1
Content Type: article
Copyright: © 2017 Elsevier Ltd. All rights reserved.